Literature DB >> 15570660

Nonmyeloablative stem cell transplant in a patient with advanced systemic sclerosis and systemic lupus erythematosus.

Ola Khorshid1, Chitra Hosing, Samer Bibawi, Naoto Ueno, John Reveille, Maureen D Mayes, Richard E Champlin.   

Abstract

Systemic sclerosis (SSc) is an uncommon connective tissue disease characterized by excessive collagen deposition within the skin and internal organs. Most patients with diffuse severe SSc are treated with immunosuppressive agents, but patients with advanced disease have very high 5-year mortality rates despite adequate therapy. We describe a patient with both diffuse cutaneous SSc and systemic lupus erythematosus who showed mixed chimerism 29 months after undergoing nonmyeloablative stem cell transplant. She experienced remission of both diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15570660

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  11 in total

1.  High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study.

Authors:  Richard A Nash; Peter A McSweeney; Leslie J Crofford; Muneer Abidi; Chien-Shing Chen; J David Godwin; Theodore A Gooley; Leona Holmberg; Gretchen Henstorf; C Fred LeMaistre; Maureen D Mayes; Kevin T McDonagh; Bernadette McLaughlin; Jerry A Molitor; J Lee Nelson; Howard Shulman; Rainer Storb; Federico Viganego; Mark H Wener; James R Seibold; Keith M Sullivan; Daniel E Furst
Journal:  Blood       Date:  2007-04-23       Impact factor: 22.113

2.  Stem cell transplantation for autoimmune diseases.

Authors:  Thomas Hügle; Thomas Daikeler
Journal:  Haematologica       Date:  2010-02       Impact factor: 9.941

3.  Autologous hematopoietic cell transplantation for systemic sclerosis - a challenge for the Canadian health care system.

Authors:  Jan Storek; Andrew Daly; Sharon A LeClercq
Journal:  CMAJ       Date:  2017-05-01       Impact factor: 8.262

4.  Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis.

Authors:  Richard A Nash; Peter A McSweeney; J Lee Nelson; Mark Wener; George E Georges; Amelia A Langston; Howard Shulman; Keith M Sullivan; Julie Lee; Gretchen Henstorf; Rainer Storb; Daniel E Furst
Journal:  Arthritis Rheum       Date:  2006-06

Review 5.  [Allogeneic stem cell transplantation : An option for autoimmune diseases?]

Authors:  S Wirths; W Bethge; J C Henes
Journal:  Z Rheumatol       Date:  2016-10       Impact factor: 1.372

Review 6.  Hematopoietic stem cell transplantation for auto immune rheumatic diseases.

Authors:  Subramanian Ramaswamy; Sandeep Jain; Vinod Ravindran
Journal:  World J Transplant       Date:  2016-03-24

7.  Haematopoietic stem cell transplantation for vasculitis including Behcet's disease and polychondritis: a retrospective analysis of patients recorded in the European Bone Marrow Transplantation and European League Against Rheumatism databases and a review of the literature.

Authors:  Thomas Daikeler; Ina Kötter; Chiara Bocelli Tyndall; Jane Apperley; Andishe Attarbaschi; Philippe Guardiola; Alois Gratwohl; Esa Jantunen; Alberto Marmont; Ferdinando Porretto; Maurizio Musso; Britta Maurer; Nadia Rinaldi; Riccardo Saccardi; Alan Tyndall
Journal:  Ann Rheum Dis       Date:  2006-09-01       Impact factor: 19.103

8.  Allogeneic stem cell transplantation for rheumatic autoimmune diseases.

Authors:  Thomas Hügle; Jacob M van Laar
Journal:  F1000 Med Rep       Date:  2010-03-25

9.  Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation.

Authors:  J A Snowden; R Saccardi; M Allez; S Ardizzone; R Arnold; R Cervera; C Denton; C Hawkey; M Labopin; G Mancardi; R Martin; J J Moore; J Passweg; C Peters; M Rabusin; M Rovira; J M van Laar; D Farge
Journal:  Bone Marrow Transplant       Date:  2011-10-17       Impact factor: 5.483

Review 10.  Stem cell transplantation for rheumatic autoimmune diseases.

Authors:  Thomas Hügle; Jacob M van Laar
Journal:  Arthritis Res Ther       Date:  2008-10-10       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.